Drug Library Category

ISO 17025–ACCREDITED LABORATORY ENVIRONMENT

Cardiovascular Drugs DMPK and Bioanalytical Services

Creative Proteomics provides DMPK, bioanalytical, metabolite profiling, and biomarker-related support for cardiovascular drug research. This section of our drug library helps researchers explore analytical service options for ACE inhibitors, ARBs, calcium channel blockers, beta-blockers, anticoagulants/antiplatelet agents, lipid-lowering agents, and related cardiovascular compounds.

Cardiovascular drug studies often involve more than systemic parent-drug measurement. Depending on the drug class and study objective, researchers may need to evaluate active metabolites, CYP/transporter interactions, parent-metabolite ratios, anticoagulant or antiplatelet readouts, lipid pathway biomarkers, or vascular response markers.

Explore Cardiovascular Drug Classes Discuss Your Study

Drug-Class EntryStart from ACE inhibitors, ARBs, beta-blockers, calcium channel blockers, or lipid-lowering agents.

DDI & Transporter AwareConnect exposure with CYP metabolism, transporter interactions, and parent-metabolite ratios.

Response-MatchedMap analytical needs to coagulation readouts, lipid pathway markers, or vascular response indicators.

Cardiovascular Study Logic

💊

Parent Drug / Drug ClassACE inhibitors, ARBs, beta-blockers, CCBs, statins, anticoagulants

🧪

Metabolites & BiotransformationActive metabolites, CYP-mediated products, glucuronide conjugates

📈

PK / Exposure PatternPlasma, serum, tissue distribution, parent-metabolite ratios

🧬

Mechanism & ResponseCoagulation, lipid, vascular, and cardiac-response biomarkers

Explore Subcategories

Navigate Cardiovascular Drug Classes

Use these entry points to move from the broad cardiovascular category into more specific drug classes and analytical support pages.

❤️

ACE Inhibitors

Support for parent-drug quantification, active metabolite analysis, and exposure profiling of angiotensin-converting enzyme inhibitors.

EnalaprilLisinoprilRamiprilCaptopril

Explore ACE Inhibitors →

🩸

Angiotensin II Receptor Blockers

Analytical workflows for ARBs where parent-drug exposure, metabolite profiling, and matrix-specific methods may be needed.

LosartanValsartanIrbesartanTelmisartan

Explore ARBs →

⚡

Calcium Channel Blockers

Bioanalytical support for dihydropyridine and non-dihydropyridine CCBs, including CYP metabolism and active metabolite assessment.

AmlodipineNifedipineVerapamilDiltiazem

Explore Calcium Channel Blockers →

💓

Beta-Blockers

Exposure and metabolite analysis for β-adrenergic receptor antagonists with varied lipophilicity and clearance routes.

MetoprololAtenololPropranololCarvedilol

Explore Beta-Blockers →

🩹

Anticoagulants / Antiplatelet Agents

Support for quantifying parent drugs, active metabolites, and coagulation- or platelet-related readouts.

WarfarinRivaroxabanApixabanClopidogrel

Explore Anticoagulants / Antiplatelet →

💊

Lipid-Lowering Agents (Statins)

DMPK and metabolite support for statins and other lipid-modulating compounds, including CYP/transporter interaction profiling.

AtorvastatinSimvastatinRosuvastatinPravastatin

Explore Lipid-Lowering Agents →

Common Research Questions

What Cardiovascular Researchers Need to Resolve

Cardiovascular DMPK projects often start with a drug-class-specific analytical question. These questions guide whether the workflow should focus on targeted quantification, metabolite profiling, DDI assessment, or response-linked biomarker analysis.

Parent drug or active metabolite?Are the relevant analytes limited to the parent drug, or should active metabolites, prodrug conversion products, or glucuronide conjugates also be included?

CYP metabolism involved?Is CYP-mediated biotransformation a major clearance route, and should metabolite profiling or CYP phenotyping be part of the study?

Transporter interactions?Does the drug interact with OATP, P-gp, or other transporters that affect disposition, tissue exposure, or DDI risk?

Parent-metabolite ratios?Are parent-to-metabolite ratios meaningful for interpreting exposure, bioactivation, or clearance in the study context?

Coagulation or platelet readouts?For anticoagulants or antiplatelet agents, are coagulation parameters, platelet function indicators, or related biomarkers needed?

Lipid or vascular response markers?Are lipid pathway biomarkers, vascular function indicators, or cardiac response markers needed alongside exposure data?

Exposure • Mechanism • Response

Connecting Drug Exposure with Cardiovascular Mechanism and Response

Measuring parent-drug or metabolite concentration provides one part of the picture. Many cardiovascular drug studies also require pathway-associated readouts to interpret whether exposure aligns with expected pharmacological activity, off-target effects, or DDI-related changes.

Exposure LayerParent drug, active metabolites, prodrug conversion, systemic concentration

→

Mechanism LayerRAAS modulation, calcium channel blockade, β-receptor antagonism, coagulation cascade

Disposition ContextCYP metabolism, transporter-mediated uptake/efflux, hepatic clearance, renal excretion

→

Response LayerBlood pressure-related readouts, coagulation parameters, lipid profiles, vascular markers

Analytical NeedLC-MS/MS quantification, MetID, CYP/transporter assays, biomarker panels

→

Study InterpretationExposure-response context, DDI assessment, pathway-linked readouts

The analytical question in cardiovascular research is often not just "how much drug is present," but whether the measured exposure accounts for active metabolites, prodrug activation, CYP/transporter-mediated interactions, and response-linked biomarker changes.

Example Cardiovascular Contexts and Readouts

Research Focus	Potential Readouts
Antihypertensive exposure interpretation	Parent drug, active metabolites, renin-angiotensin-aldosterone-related markers
Anticoagulant/antiplatelet research	Parent drug, active/inactive metabolites, PT/INR, aPTT, platelet aggregation indicators
Lipid-lowering agent studies	Parent drug, active metabolites, LDL-C, HDL-C, total cholesterol, triglyceride profiles
DDI-related cardiovascular studies	CYP isoform-specific metabolites, transporter substrate profiling, parent-metabolite ratio shifts
Vascular or cardiac response	Endothelial function markers, cardiac troponin-related readouts, inflammatory and vascular remodeling indicators

Bioanalytical and DMPK Service Capabilities

Service Modules for Cardiovascular Drug Studies

These service modules connect cardiovascular research questions with analytical routes for parent compounds, active metabolites, CYP/transporter profiling, and response-linked readouts.

Parent Drug and Metabolite Quantification

Targeted quantification of cardiovascular parent drugs, active metabolites, prodrug forms, and related analytes in biological matrices.

Parent-drug measurement
Active metabolite quantification
Parent-metabolite ratio analysis
Multi-analyte assay development

LC-MS/MS Quantification Parent-Metabolite Panels

PK, DDI, and Exposure Assessment

Support for exposure questions driven by CYP metabolism, transporter interactions, and drug-class-specific disposition.

Plasma and serum PK analysis
CYP/transporter interaction support
Tissue or organ exposure
DDI-related exposure interpretation

Plasma & Serum Quantification DDI Support Transporter Interaction

Metabolite Identification and Biotransformation

Clarify how cardiovascular drugs are metabolized, activated as prodrugs, cleared, or generate active metabolites in biological systems.

Phase I / II metabolite support
Prodrug activation profiling
CYP isoform-specific metabolites
Active metabolite confirmation

Metabolite Identification Phase I / II Metabolites

Coagulation, Lipid, and Response Biomarkers

Analytical support for coagulation readouts, lipid pathway biomarkers, vascular markers, and response-linked indicators.

Coagulation parameter analysis
Lipid profile quantification
Vascular and cardiac response markers
Custom biomarker panel development

Custom LC-MS/MS Method Forced Degradation

Integrated Analysis

Why Cardiovascular Drug Studies Require Integrated Analysis

Cardiovascular therapeutics differ widely in mechanism, metabolic route, transporter profile, and response endpoints. A useful analytical workflow should align the drug class with the right analytes, exposure context, and mechanism-linked outputs.

From cardiovascular drug class to study-ready workflow

❤️

Drug classACE inhibitor, ARB, CCB, beta-blocker, anticoagulant, antiplatelet, statin, or proprietary cardiovascular compound.

🧪

Relevant analyte setParent drug, active metabolite, prodrug, conjugates, pathway-linked endogenous markers, or coagulation/lipid readouts.

📍

Matrix and exposure contextPlasma, serum, tissue, organ homogenate, or study-specific biological matrix.

📊

Analytical outputQuantitative exposure data, metabolite profiles, DDI assessment, or biomarker-linked interpretation.

ACE inhibitors / ARBs

Often involve prodrug activation, active metabolite measurement, RAAS-related readouts, and renal-function context.

Calcium channel blockers / Beta-blockers

Frequently require CYP metabolism profiling, parent-metabolite ratio assessment, and transporter interaction evaluation.

Anticoagulants / Antiplatelet agents

May require coagulation parameter measurement, active/inactive metabolite discrimination, and DDI-linked exposure interpretation.

Lipid-lowering agents

Can involve statin acid/lactone profiling, OATP/P-gp transporter assessment, lipid panel quantification, and active metabolite confirmation.

Cardiovascular DMPK Support Spanning Drug Classes and Analytical Workflows

Creative Proteomics provides integrated bioanalytical and DMPK services across ACE inhibitors, ARBs, calcium channel blockers, beta-blockers, anticoagulants, antiplatelet agents, statins, and other cardiovascular drug classes — from targeted quantification and metabolite profiling to DDI assessment and biomarker-linked interpretation.

Ready to Quantify Your Lead Compound or Metabolite?

Share your matrix type, sample count, and expected range—feasibility routing will confirm whether direct quantification is fit-for-purpose or method development is recommended.

Want to browse compounds, matrices, and assay coverage? Explore the Library →